Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLB1 | P16278 | 2/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.42 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.40 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278572 | 1.00 | GBA1 (0.43) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL3279555 | 1.00 | GBA1 (0.43) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL3233892 | 1.00 | GBA1 (0.43) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL3278567 | 1.00 | GBA1 (0.43) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL20660346 | 0.85 | SLC6A1 (0.39) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL20660344 | 0.85 | SLC6A1 (0.39) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL3619899 | 0.85 | SLC6A1 (0.39) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL22389582 | 0.85 | SLC6A1 (0.39) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL22389581 | 0.85 | SLC6A1 (0.39) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL3619898 | 0.85 | SLC6A1 (0.39) | GBA1GAAGLB1PYGLGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
| EP-3400228-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10059718-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2018-08-28 | — | — | US | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | GBA1 4124/4885GAA 2995/4885GLB1 1936/4885 |
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | GBA1 3235/4885GAA 2044/4885GLB1 4021/4885 |
| US-10059718-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | GBA1 3235/4885GAA 2044/4885GLB1 4021/4885 |
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | GBA1 329/4885GAA 405/4885GLB1 1788/4885 |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | GBA1 3235/4885GAA 2044/4885GLB1 4021/4885 |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | GBA1 1867/4885GAA 1815/4885GLB1 1596/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | GBA1 329/4885GAA 405/4885GLB1 1788/4885 |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | GBA1 3235/4885GAA 2044/4885GLB1 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.